Industry Focus - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

Industry Focus — Business
Industry Focus

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Latest Episodes:

Healthcare: Who Had The Better Quarter, Tandem Diabetes or Teladoc? May 01, 2019

Show notes

In this earnings brawl episode of Industry Focus Healthcare, diabetes disruptor Tandem Diabetes faces off against telehealth titan Teladoc. Place your bets, because the winner may surprise you.

Check out more of our content here:

CG: The Future of Cars and the Mercadolibre of Africa Apr 30, 2019

Show notes

Uxin battles a recent short report and Jumia is investing big in Africa. On this week’s episode of Industry Focus: Consumer Goods host Jason Moser and Fool analysts Emily Flippen and Joey Solitro discuss the state of affairs with the leading used car platform China used car company and take a closer look at how Jumia is capitalizing on Africa’s developing middle class. Plus the team takes a listener question on how investors should be viewing Chinese electric car company NIO

Check out more of our content here:

Financials: Financial Literacy Month Comes to a Close Apr 29, 2019

Show notes

In addition to earnings season, we’re also in the final days of financial literacy month. April is financial literacy month, so in this episode of Industry Focus: Financials, Fool.com contributor Matt Frankel, CFP sat down with Elizabeth Overbay, Chief Operating Officer of Goldman Sachs’ (NYSE: GS) consumer banking division and Dustin Cohn, Head of Brand and Marketing Communications for Marcus by Goldman Sachs to talk about the problem of financial literacy in America and what they’re doing to fix it. Plus, Frankel and host Jason Moser discuss first-quarter results from fintech heavyweights Visa (NYSE: V) and PayPal (NASDAQ: PYPL), and as always, let listeners know what stocks they’re watching this week.

Check out more of our content here:

Tech: Let's Get Millennial Apr 26, 2019

Show notes

A lot of ink has been spilled about the things millennials are killing -- napkins, bar soap -- but as the generation of people born between the early 1980s and the early 2000s age into becoming the biggest generation in the workforce, investors want to know: what businesses will enjoy huge tailwinds? We introduce our "Millennial Basket" -- three companies that seem to have plenty of room to grow based on where young folks are spending their dough.

Stocks: EB, UPWK, MTCH

Check out more of our content here:

Energy: Chart-ing a Course in LNG & the US Reaffirms Iran Sactions Apr 25, 2019

Show notes

After issuing 6 month exemptions, the U.S. pledges to fully enforce sanctions against Iranian oil exports. What does this mean for investors? In addition, huge spreads between the price of natural gas around the world has investment in liquefied natural gas (LNG) exploding. Motley Fool Contributor Jason Hall and Industry Focus host Nick Sciple discuss Chart Industries, a key provider of equipment used to cool and transform natural gas from a gaseous state to a liquid, and what opportunities it may provide to investors.

Stocks Mentioned: GTLS

Check out more of our content here:

Thanks to Molekule for supporting Industry Focus. Get $75 off your first order at http://www.molekule.com code fool75.

Healthcare: Is This Highly-Anticipated Gene Therapy In Trouble? Apr 24, 2019

Show notes

An infant participating in Novartis' Zolgensma trial has died, raising questions ahead of an expected FDA decision next month for this one-and-done treatment for spinal muscular atrophy. Here's what you should know. Also, why investors should ignore Intuitive Surgical's first quarter earnings miss and buy shares on sale.

Check out more of our content here:

CG: Is the T-Mobile/Sprint Deal in Trouble? And Making Sense of Streaming Services Apr 23, 2019

Show notes

T-Mobile and Sprint have faced opposition from federal regulators over their planned $26.5 billion merger. Speculation that the deal may not be approved has led Sprint to send a statement to the Department of Justice saying that if the deal gets denied, it may not be able to survive. Fool Contributor Daniel Kline joins Shannon Jones to break that down and to take some time to sort out the streaming video industry.

Check out more of our content here:

Thanks to Molekule for supporting Industry Focus. Get $75 off your first order at http://www.molekule.com code fool75.

Financials: American Express Has Changed and Bank Earnings Continue Apr 22, 2019

Show notes

On this episode of Industry Focus: Financials, Fool.com contributor Matt Frankel, CFP sits down with Gunther Bright, Executive Vice President, Merchant Services U.S. for American Express to discuss how Amex has evolved in recent years. After, Frankel and host Jason Moser discuss a trio of earnings from Bank of America (NYSE: BAC), Morgan Stanley (NYSE: MS), and Travelers (NYSE: TRV) and answer a listener question about investing in wealth management firms. And, as always, we close out the show with two stocks we’re keeping our eye on now.

Check out more of our content here:

Thanks to Molekule for supporting Industry Focus. Get $75 off your first order at http://www.molekule.com code fool75.

Energy: Chevron Writes Anadarko a Check, Kinder Morgan Reports Earnings, and Oil Company Earnings Previews Apr 18, 2019

Show notes

Last Friday, Chevron announced a $33 billion acquisition of Anadarko Petroleum, one of the biggest energy mergers in years. Motley Fool Contributor Matt Dilallo and Industry Focus host Nick Sciple break down the deal, take a look at Kinder Morgan’s most recent earnings report, and preview upcoming earnings from some of their favorite oil companies.

Stocks Mentioned: CVX, APC, KMI, HES, XOM, COP

Check out more of our content here:

Healthcare: How Marijuana Legalization Impacted OrganiGram and Aphria's Latest Results Apr 17, 2019

Show notes

Marijuana stocks OrganiGram and Aphria reported quarterly earnings this week - here's what you should know. Also, Abbott locks horns with DexCom in diabetes and what's next for Bristol-Myers' now that its Celgene acquisition is official.

Check out more of our content here:

Related Podcasts